Rachid Baz, MD
Hematology & Oncology · Tampa, FLNPI 1831393875
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Hikma Pharmaceuticals USA at 38.5% of the total. Reporting peaked in 2023 at $19,406 and has fallen 77.5% since, to $4,375 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $1043.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hikma Pharmaceuticals USA$29K
- GSK$18K
- Sanofi$13K
- E.r. Squibb & Sons, L.L.C.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Janssen Scientific Affairs, LLC$2K
- plus $7K from 12 others
Across 355 payments — averaging $8295.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.2M
- AbbVie$935K
- Regeneron$383K
- Janssen Research & Development, LLC$291K
- E.r. Squibb & Sons, L.L.C.$50K
- Karyopharm Therapeutics Inc.$29K
- plus $34K from 3 others
What the payments were for
- Consulting fees$41,18354%
- Speaking & faculty fees$11,25015%
- Travel & lodging$20,29927%
- Food & beverage$3,4224%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hikma Pharmaceuticals USA | 9 | $29,285 |
| GSK | 9 | $17,656 |
| Sanofi | 15 | $13,395 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,095 |
| Janssen Scientific Affairs, LLC | 2 | $2,053 |
| Johnson & Johnson | 10 | $1,903 |
| Pfizer | 1 | $1,750 |
| Genentech, Inc. | 1 | $1,320 |
| Karyopharm Therapeutics Inc. | 3 | $451 |
| Amgen | 6 | $432 |
| Bristol Myers Squibb | 6 | $424 |
| Stemline Therapeutics Inc. | 1 | $127 |
| Lilly USA, LLC | 3 | $125 |
| AbbVie | 1 | $118 |
| Gilead | 1 | $114 |
| Beigene USA, Inc. | 1 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,155 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 340 | $4,833,320 |
| PomalystPomalidomide | 190 | $4,371,151 |
| RevlimidLenalidomide | 198 | $3,653,517 |
| ImbruvicaIbrutinib | 20 | $328,152 |
| VenclextaVenetoclax | 16 | $270,950 |
| NinlaroIxazomib Citrate | 14 | $175,697 |
| Acyclovir | 140 | $1,940 |
| Oxycodone Hcl | 103 | $1,796 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $1,383 |
| CholestyramineCholestyramine (With Sugar) | 12 | $1,113 |
| Pregabalin | 16 | $635 |
| Dexamethasone | 32 | $505 |
| ValacyclovirValacyclovir Hcl | 13 | $456 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $335 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USALenalidomide | $29,285 | $4,833,320340 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $3,820 | $4,371,151190 claims |
| Bristol Myers SquibbRevlimid | $424 | $3,653,517198 claims |
| AbbVieVenclexta | $118 | $270,95016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $3,095 | $175,69714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.